Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-674, 2011. ,
DOI : 10.1016/j.cell.2011.02.013
Radiopharmaceuticals as probes to characterize tumour tissue, CrossRef] [PubMed] 3. Mellstedt, H. Monoclonal antibodies in human cancer, pp.537-561, 2003. ,
DOI : 10.1038/nm.2935
Antibodies directed against receptor tyrosine kinases, mAbs, vol.25, issue.4, pp.838-851 ,
DOI : 10.1158/0008-5472.CAN-10-2274
Receptor Tyrosine Kinases and Anticancer Therapy, Current Pharmaceutical Design, vol.11, issue.9, pp.1139-1149, 2005. ,
DOI : 10.2174/1381612053507611
Targeting Tyrosine Kinases in Cancer: The Second Wave, Science, vol.312, issue.5777, pp.1175-1178, 2006. ,
DOI : 10.1126/science.1125951
Designing the Magic Bullet? The Advancement of Immuno-PET into Clinical Use, Journal of Nuclear Medicine, vol.54, issue.8, pp.1171-1174, 2013. ,
DOI : 10.2967/jnumed.113.126086
Continuous cultures of fused cells secreting antibody of predefined specificity [CrossRef] [PubMed] 9. Teillaud, J.-L. Engineering of monoclonal antibodies and antibody-based fusion proteins: Successes and challenges, Nature Expert Opin. Biol. Ther, vol.256, issue.5, pp.495-497, 1975. ,
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001. ,
DOI : 10.1056/NEJM200103153441101
Immunotherapy of Non-Hodgkin's lymphomas. Hematol, Am. Soc. Hematol. Educ. Program, pp.221-240, 2001. ,
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies., Proc. Natl. Acad. Sci. USA 1979, pp.1438-1442 ,
DOI : 10.1073/pnas.76.3.1438
Recent advances and future advances in time-of-flight PET, Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, vol.580, issue.2, pp.919-924, 2007. ,
DOI : 10.1016/j.nima.2007.06.038
Recent developments in PET detector technology, Physics in Medicine and Biology, vol.53, issue.17, pp.287-317, 2008. ,
DOI : 10.1088/0031-9155/53/17/R01
URL : http://iopscience.iop.org/article/10.1088/0031-9155/53/17/R01/pdf
Immuno-PET of Cancer: A Revival of Antibody Imaging, Journal of Nuclear Medicine, vol.52, issue.8, pp.1171-1172, 2011. ,
DOI : 10.2967/jnumed.111.089771
PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET, Tumor Biology, vol.353, issue.Suppl 1, pp.607-615, 2012. ,
DOI : 10.1056/NEJMoa050753
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications, The Oncologist, vol.12, issue.12, pp.1379-1389, 2007. ,
DOI : 10.1634/theoncologist.12-12-1379
ImmunoPET to help stratify patients for targeted therapies and to improve drug development, European Journal of Nuclear Medicine and Molecular Imaging, vol.42, issue.12, pp.2166-2168, 2016. ,
DOI : 10.1007/s00259-015-3025-6
URL : https://link.springer.com/content/pdf/10.1007%2Fs00259-016-3458-6.pdf
PET versus SPECT: strengths, limitations and challenges, Nuclear Medicine Communications, vol.29, issue.3, pp.193-207, 2008. ,
DOI : 10.1097/MNM.0b013e3282f3a515
Tumor immunotargeting using innovative radionuclides, Int. J. Mol. Sci, vol.2015, issue.16, pp.3932-3954 ,
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view, Nuclear Medicine and Biology, vol.34, issue.7, pp.757-778, 2007. ,
DOI : 10.1016/j.nucmedbio.2007.04.001
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212602/pdf
In vivo imaging with antibodies and engineered fragments, Molecular Immunology, vol.67, issue.2, pp.142-152 ,
DOI : 10.1016/j.molimm.2015.04.001
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529772/pdf
Nanobodies: Natural Single-Domain Antibodies, Annual Review of Biochemistry, vol.82, issue.1, pp.775-797, 2013. ,
DOI : 10.1146/annurev-biochem-063011-092449
Engineered Fc based antibody domains and fragments as novel scaffolds, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol.1844, issue.11, pp.1977-1982, 2014. ,
DOI : 10.1016/j.bbapap.2014.04.018
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185235/pdf
Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients, Journal of Nuclear Medicine, vol.57, issue.6, pp.867-871, 2016. ,
DOI : 10.2967/jnumed.115.169342
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma, Journal of Nuclear Medicine, vol.57, issue.1, pp.27-33, 2016. ,
DOI : 10.2967/jnumed.115.162024
Reprint of ???Protein and Cell Membrane Iodinations with a Sparingly Soluble Chloroamide, 1,3,4,6-Tetrachloro-3a,6a-Diphenylglycoluril???, Biochemical and Biophysical Research Communications, vol.425, issue.3, pp.510-518, 1978. ,
DOI : 10.1016/j.bbrc.2012.08.017
Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues, Nuclear Medicine and Biology, vol.37, issue.2, p.167, 2010. ,
DOI : 10.1016/j.nucmedbio.2009.10.004
Approaches to Improve Cellular Retention of Radiohalogen Labels Delivered by Internalising Tumour-Targeting Proteins and Peptides, Current Medicinal Chemistry, vol.10, issue.22, pp.2447-2460, 2003. ,
DOI : 10.2174/0929867033456666
Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy, Oncology Reports, vol.35, issue.6, pp.3159-3168, 2016. ,
DOI : 10.3892/or.2016.4706
A Novel Method of 18F Radiolabeling for PET, Journal of Nuclear Medicine, vol.50, issue.6, pp.991-998, 2009. ,
DOI : 10.2967/jnumed.108.060418
18 F Labeling for immuno-PET: Where speed and contrast meet, J. Nucl. Med, vol.48, pp.170-172, 2007. ,
Matching chelators to radiometals for radiopharmaceuticals, Chem. Soc. Rev., vol.30, issue.1, pp.260-290 ,
DOI : 10.1021/ic00007a024
Bifunctional chelates for metal nuclides, Q. J. Nucl. Med. Mol. Imaging, vol.52, pp.166-173, 2008. ,
89Zr-labeled compounds for PET imaging guided personalized therapy, Drug Discovery Today: Technologies, vol.8, issue.2-4, pp.53-61, 2011. ,
DOI : 10.1016/j.ddtec.2011.12.004
In vivo biodistribution and accumulation of 89Zr in mice, Nuclear Medicine and Biology, vol.38, issue.5, pp.675-681, 2011. ,
DOI : 10.1016/j.nucmedbio.2010.12.011
Mapping biological behaviors by application of longer-lived positron emitting radionuclides, Advanced Drug Delivery Reviews, vol.65, issue.8, pp.1098-1111, 2013. ,
DOI : 10.1016/j.addr.2012.10.012
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593806/pdf
A universal pretargeting system for cancer detection and therapy using bispecific antibody, Cancer Res, vol.63, pp.354-363, 2003. ,
DOI : 10.2172/898305
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy, Journal of Clinical Oncology, vol.24, issue.5, pp.823-834, 2006. ,
DOI : 10.1200/JCO.2005.03.8471
Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial, Journal of Nuclear Medicine, vol.57, issue.10, pp.1505-1511, 2016. ,
DOI : 10.2967/jnumed.116.172221
URL : https://hal.archives-ouvertes.fr/inserm-01415668
Bioorthogonal chemistry: recent progress and future directions, Chemical Communications, vol.446, issue.10, pp.1589-1600, 2010. ,
DOI : 10.1016/S0304-4165(01)00211-2
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914230/pdf
Bioorthogonal chemistry: Implications for pretargeted nuclear (PET/SPECT) imaging and therapy, Am. J. Nucl. Med. Mol. Imaging, vol.4, pp.96-113, 2014. ,
Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels???Alder Click Chemistry, Bioconjugate Chemistry, vol.22, issue.10, pp.2048-2059, 2011. ,
DOI : 10.1021/bc200288d
The Growing Impact of Bioorthogonal Click Chemistry on the Development of Radiopharmaceuticals, Journal of Nuclear Medicine, vol.54, issue.6, pp.829-832, 2013. ,
DOI : 10.2967/jnumed.112.115550
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial, The Lancet Oncology, vol.8, issue.4, pp.304-310, 2007. ,
DOI : 10.1016/S1470-2045(07)70044-X
Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial, Journal of Clinical Oncology, vol.31, issue.2, pp.31-187, 2013. ,
DOI : 10.1200/JCO.2011.41.2445
PET of Hypoxia with 89Zr-Labeled cG250-F(ab')2 in Head and Neck Tumors, Journal of Nuclear Medicine, vol.51, issue.7, pp.1076-1083, 2010. ,
DOI : 10.2967/jnumed.109.073189
ProstaScint?? scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients, The Prostate, vol.65, issue.4, pp.261-269, 1998. ,
DOI : 10.1002/1097-0142(19900415)65:8<1843::AID-CNCR2820650830>3.0.CO;2-4
PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen, Current Topics in Medicinal Chemistry, vol.13, issue.8, pp.951-962, 2013. ,
DOI : 10.2174/1568026611313080008
Prostate-specific membrane antigen as a target for cancer imaging and therapy, Q. J. Nucl. Med. Mol. Imaging, vol.59, pp.241-268, 2015. ,
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.27, issue.9, pp.2093-2105, 2014. ,
DOI : 10.1118/1.1288393
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404641/pdf
A Prospective Pilot Study of 89Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy, The Journal of Urology, vol.191, issue.5, pp.1439-1445, 2014. ,
DOI : 10.1016/j.juro.2013.10.041
Pilot study of 89 Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer ,
89 Zr-cetuximab PET imaging in patients with advanced colorectal cancer, Oncotarget, vol.6, pp.30384-30393, 2015. ,
Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors, Journal of Nuclear Medicine, vol.55, issue.7, pp.1087-1092, 2014. ,
DOI : 10.2967/jnumed.113.129056
TGF-?? Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET, Journal of Nuclear Medicine, vol.56, issue.9, pp.1310-1314, 2015. ,
DOI : 10.2967/jnumed.115.154401
Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET, Journal of Nuclear Medicine, vol.55, issue.1, pp.23-29, 2014. ,
DOI : 10.2967/jnumed.113.122630
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer, Clinical Pharmacology & Therapeutics, vol.87, issue.5, pp.586-592, 2010. ,
DOI : 10.1162/153535003322556877
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis, Annals of Oncology, vol.24, issue.1, pp.101-108, 2013. ,
DOI : 10.1093/annonc/mds248
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer, Annals of Oncology, vol.20, issue.12, pp.1953-1958, 2009. ,
DOI : 10.1093/annonc/mdp263
Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients, Medical Oncology, vol.14, issue.4, pp.31-214, 2014. ,
DOI : 10.3747/co.2007.131
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging, Journal of Nuclear Medicine, vol.50, issue.6, pp.974-981, 2009. ,
DOI : 10.2967/jnumed.108.060392
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules, Journal of Nuclear Medicine, vol.51, issue.6, pp.892-897, 2010. ,
DOI : 10.2967/jnumed.109.073239
Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer, J. Nucl. Med, vol.64, issue.54, pp.1869-1875, 2013. ,
DOI : 10.2967/jnumed.112.118612
URL : http://jnm.snmjournals.org/content/54/11/1869.full.pdf
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?, Frontiers in Pharmacology, vol.5, 2016. ,
DOI : 10.1038/nprot.2010.13
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial, Annals of Oncology, vol.27, issue.4 ,
DOI : 10.1093/annonc/mdv577
The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors, Neoplasia, vol.8, issue.3, pp.190-198, 2006. ,
DOI : 10.1593/neo.05733
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance, Acta Histochemica, vol.108, issue.1, pp.19-24, 2006. ,
DOI : 10.1016/j.acthis.2006.01.003
et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res, pp.3381-3385, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-01597856
The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors, Clinical Immunology, vol.141, issue.3, pp.338-347, 2011. ,
DOI : 10.1016/j.clim.2011.08.013
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Medical Oncology, vol.10, issue.3, pp.682-688, 2011. ,
DOI : 10.1158/1078-0432.CCR-04-0428
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape, Science Translational Medicine, vol.27, issue.36 ,
DOI : 10.1200/JCO.2009.23.4799
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-?? and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway, Blood, vol.110, issue.1, pp.296-304, 2007. ,
DOI : 10.1182/blood-2006-10-051482
URL : http://www.bloodjournal.org/content/bloodjournal/110/1/296.full.pdf
Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies, Cancer Research, vol.75, issue.14, pp.2928-2936, 2015. ,
DOI : 10.1158/0008-5472.CAN-14-3477
URL : http://cancerres.aacrjournals.org/content/canres/75/14/2928.full.pdf
Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes, Bioconjugate Chemistry, vol.26, issue.10, pp.2062-2069 ,
DOI : 10.1021/acs.bioconjchem.5b00318
Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer, Cancer Research, vol.76, issue.2, pp.472-479, 2016. ,
DOI : 10.1158/0008-5472.CAN-15-2141
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, Eur. J. Nucl. Med. Mol. Imaging, vol.41, pp.1593-1602, 2014. ,
Pharmacokinetics and dosimetry studies for optimization of pretargeted radioimmunotherapy in CEA-expressing advanced lung cancer patients, p.84 ,
URL : https://hal.archives-ouvertes.fr/hal-01258870
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin???s lymphoma using 89Zr-ibritumomab tiuxetan and PET, European Journal of Nuclear Medicine and Molecular Imaging, vol.37, issue.4 Suppl, pp.512-520, 2012. ,
DOI : 10.1007/s00259-009-1297-4
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography, European Journal of Nuclear Medicine and Molecular Imaging, vol.21, issue.Suppl 1, pp.1337-1345, 2006. ,
DOI : 10.1007/s00259-006-0160-0